Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Market Insights, Epidemiology and Market Forecast–2028
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Market Insights, Epidemiology and Market Forecast–2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of HR-positive/HER2-negative breast cancer from 2017 to 2028 segmented by the seven major markets.
HR-positive/HER2-negative breast cancer is the most common form of breast cancer. This type accounts for a higher percentage of all breast cancers. Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Addition to this, there is another factor which is also responsible for breast cancer which is known as human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. There are more number of cases for breast cancer in women observed in comparison to the men.
Geography Covered
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Disease Understanding and Treatment Algorithm
HR-positive cancer is usually treated with Endocrine therapies or a combination of hormone therapy with targeted therapy to help stop tumor growth first. However, sometimes cancer outsmarts the treatment and becomes resistant to hormonal therapy and stops working. Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic effects depending on the tissue, cell or promoter.
Currently there are number of classes of anti-estrogenic agents available for patients with early, advanced, or metastatic breast cancer which includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.
ETs are a common first-line treatment in advanced or metastatic breast cancer (MBC), resistance inevitably develops. Some patients may develop resistance to ET with one agent class, a response to treatment may occur with exposure to another class. Sequential ET is preferred in postmenopausal women with HR+, HER2- MBC. Guidelines currently recommend Aromatase Inhibitors (AIs) with the CDK4/6 inhibitors, palbociclib or ribociclib, or fulvestrant as a first-line ET option. As a second-line ET option, fulvestrant in combination with palbociclib or abemaciclib is recommended for patients with prior adjuvant ET exposure or patients who received ET in the metastatic setting. However there is one drawback of Endocrine therapies that patients become resistance to this after continues use. For this Targeted CDK4/6 Inhibitors are used as First-Line Regimens. In addition to this, First-Line Regimens, mTOR Inhibitors and Akt Inhibitors also recommended.
The DelveInsight’s Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market report gives a thorough understanding of the HR-positive/HER2-negative by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HR-positive/HER2-negative in the US, Europe, and Japan.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Epidemiology
The HR-positive/HER2-negative epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of Breast Cancer in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the 7MM and Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the 7MM] of HR-positive/HER2-negative in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight’s epidemiology model for HR-positive/HER2-negative Breast Cancer has assessed that total incident population of Breast Cancer in the 7MM is expected to grow at CAGR of 0.83%, during study period [2017–2028]. DelveInsight’s estimate suggests the United States show higher incidence of Breast Cancer. As per the DelveInsight’s estimation, in 2017, among the EU-5 countries, Spain has the least number of breast cancer incident cases. According to the DelveInsight’s analyst, among the 7MM countries, Japan accounts for the second highest breast cancer incident cases.
In addition to this according to DelveInsight’s epidemiology model, based on the menopausal status of women suffering from breast cancer, in the 7MM, the higher number of cases were observed for the postmenopausal Breast cancer, accounting for 70–80% of the cases, while premenopausal women contributed a significantly lesser proportion of the patients. DelveInsight’s estimates suggests that based on stage-specific incidence of breast cancer in postmenopausal women, Stage IIIb,c and IV-specific breast cancer were observed to be less in number of patients. On the other hand, Stage I-IIIa together accounted for majority of the patient pool.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Drug Chapters
This segment of the HR-positive/HER-Negative report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
For the treatment of HR-positive/HER-Negative there are many drugs are available. Ibrance (Palbociclib; Pfizer), PIQRAY (Alpelisib; BYL719; Novartis), Lynparza (olaparib; AstraZeneca Pharmaceuticals), Verzenio (Abemaciclib; Eli Lilly), Kisqali (Ribociclib; LEE011: Novartis Pharmaceuticals), Afinitor (Everolimus; Novartis), Faslodex (Fulvestrant Injection: AstraZeneca) and many more approved for the management of the HR-Positive/Her2negative breast cancer.
Ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. IBRANCE currently is approved in more than 90 countries.
It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or fulvestrant in patients with disease progression following endocrine therapy for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
PIQRAY (BYL719; ALPESLIB) is an investigational, orally bioavailable, alpha-specific PI3K inhibitor developed by Novartis. In breast cancer cell lines harboring PIK3CA mutations, BYL719 has been shown to potentially inhibit the PI3K pathway and have antiproliferative effects. In addition, cancer cell lines with PIK3CA mutations were more sensitive to BYL719 than those without the mutation across a broad range of different cancers.
Verzenio (Abemaciclib) is indicated for the treatment of women with hormone receptor (HR)-positive in combination with fulvestrant. There are other kinase inhibitors recommended in combination to the conventional endocrine therapies. KISQALI is a kinase inhibitor used in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive breast cancer (BC). It is also used for human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.
There are other approved drugs in the market for the management of HR-positive/Her2-negative breast cancer.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Market Outlook
The HR-Positive/HER2-Negative Breast cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
As per the assessment by DelveInsight’s analysts, it has been observed that the market size of HR-positive/HER2-negative Breast in the 7MM countries was observed to be USD 5,237.2 million in 2017. Among the 7MM countries, the United States had the highest market size of HR-positive/HER2-negative breast cancer in 2017, of the total market. At present, the growth of market size for HR-positive/HER2-negative breast cancer is attributed to drugs that have been approved for HR-positive breast cancer by the US FDA.
As per the DelveInsight’s analyst, among the 7MM countries, Japan had the second highest market size of HR-positive/HER2-negative breast cancer in 2017. Among the EU-5 countries, Germany had the highest market size of HR-positive/HER2-negative breast cancer in 2017. At present, the growth of market size for HR-positive/HER2-negative breast cancer is attributed to drugs that have been approved for HR-positive breast cancer in EU-5 countries. The market size for HR-positive/HER2-negative breast cancer. At present, the growth of market size for HR-positive/HER2-negative breast cancer is attributed to drugs that have been approved for HR-positive breast cancer in EU-5 countries.
Advancement in development of novel drug candidate by various pharmaceutical companies the dynamics of HR-positive/HER2-Negative breast cancer market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019–2028. There are presently many drugs focused on the treatment of HR-positive/HER2-Negative breast cancer, which are expected to enter the market during the forecast period [2019–2028].
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of HR-positive/Her2-negative breast cancer market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and advancement in the research and development of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for HR-positive/HER2-negative breast cancer.
More than a dozen companies have shifted their focus towards this therapeutic area. To name a few: Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Pharmaceuticals, Merck Sharp & Dohme Corp, Eagle Pharmaceuticals and others.
Tesetaxel is an investigational agent developed by Odonate Therapeutics, belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. This is an orally administered chemotherapy. Odonate is hoping to qualify as a New Chemical Entity (NCE) if and when a New Drug Application (NDA) is submitted, retains the same taxane core as the approved taxanes, but includes the addition of two novels, nitrogen-containing functional group. This new formulation does not contain solubilizing agents contained in other taxane formulations which are known to cause hypersensitivity reactions. This is currently being accessed in phase III.
Sacituzumab govitecan (IMMU-132: Immunomedics) is an advanced product candidate, which is a novel, first-in-class antibody-drug conjugate (ADC). Sacituzumab govitecan is an ADC that contains SN-38, the active metabolite of irinotecan, approved by many Health Authorities, including the US Food and Drug Administration (FDA) as a chemotherapeutic for patients with cancer. SN-38 cannot be given directly to patients because of its toxicity and poor solubility.This novel drug is currently is in Phase III clinical developmental stage.
SHR6390 (Jiangsu HengRui Medicine) is Cyclin-dependent kinases 4 and 6 (CDK4/6) of cell cycle progression and are dysregulated in cancers. Inhibition of CDK4/6 induces G1 phase cell cycle arrest, therefore retards tumor growth. This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are up-regulated in many tumor cell types and play a key role in the regulation of cell cycle progression. SHR6390 has been recently accessed in phase II clinical trials.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Report Insights
DelveInsight’s ‘Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer- Market Insights, Epidemiology and Market Forecast–2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of HR-positive/HER2-negative breast cancer from 2017 to 2028 segmented by the seven major markets.
HR-positive/HER2-negative breast cancer is the most common form of breast cancer. This type accounts for a higher percentage of all breast cancers. Hormone receptors are proteins that receive hormone signals and tell the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. If cancerous cells get signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Addition to this, there is another factor which is also responsible for breast cancer which is known as human epidermal growth factor receptor 2 (HER2). Human epidermal growth factor receptor-2 is a gene that helps control how cells grow, divide, and repair themselves. There are more number of cases for breast cancer in women observed in comparison to the men.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Disease Understanding and Treatment Algorithm
HR-positive cancer is usually treated with Endocrine therapies or a combination of hormone therapy with targeted therapy to help stop tumor growth first. However, sometimes cancer outsmarts the treatment and becomes resistant to hormonal therapy and stops working. Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic effects depending on the tissue, cell or promoter.
Currently there are number of classes of anti-estrogenic agents available for patients with early, advanced, or metastatic breast cancer which includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.
ETs are a common first-line treatment in advanced or metastatic breast cancer (MBC), resistance inevitably develops. Some patients may develop resistance to ET with one agent class, a response to treatment may occur with exposure to another class. Sequential ET is preferred in postmenopausal women with HR+, HER2- MBC. Guidelines currently recommend Aromatase Inhibitors (AIs) with the CDK4/6 inhibitors, palbociclib or ribociclib, or fulvestrant as a first-line ET option. As a second-line ET option, fulvestrant in combination with palbociclib or abemaciclib is recommended for patients with prior adjuvant ET exposure or patients who received ET in the metastatic setting. However there is one drawback of Endocrine therapies that patients become resistance to this after continues use. For this Targeted CDK4/6 Inhibitors are used as First-Line Regimens. In addition to this, First-Line Regimens, mTOR Inhibitors and Akt Inhibitors also recommended.
The DelveInsight’s Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market report gives a thorough understanding of the HR-positive/HER2-negative by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for HR-positive/HER2-negative in the US, Europe, and Japan.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Epidemiology
The HR-positive/HER2-negative epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight’s report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of Breast Cancer in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Incidence of Breast Cancer Cases by Menopausal Status in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the 7MM, Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the 7MM and Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the 7MM] of HR-positive/HER2-negative in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight’s epidemiology model for HR-positive/HER2-negative Breast Cancer has assessed that total incident population of Breast Cancer in the 7MM is expected to grow at CAGR of 0.83%, during study period [2017–2028]. DelveInsight’s estimate suggests the United States show higher incidence of Breast Cancer. As per the DelveInsight’s estimation, in 2017, among the EU-5 countries, Spain has the least number of breast cancer incident cases. According to the DelveInsight’s analyst, among the 7MM countries, Japan accounts for the second highest breast cancer incident cases.
In addition to this according to DelveInsight’s epidemiology model, based on the menopausal status of women suffering from breast cancer, in the 7MM, the higher number of cases were observed for the postmenopausal Breast cancer, accounting for 70–80% of the cases, while premenopausal women contributed a significantly lesser proportion of the patients. DelveInsight’s estimates suggests that based on stage-specific incidence of breast cancer in postmenopausal women, Stage IIIb,c and IV-specific breast cancer were observed to be less in number of patients. On the other hand, Stage I-IIIa together accounted for majority of the patient pool.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Drug Chapters
This segment of the HR-positive/HER-Negative report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
For the treatment of HR-positive/HER-Negative there are many drugs are available. Ibrance (Palbociclib; Pfizer), PIQRAY (Alpelisib; BYL719; Novartis), Lynparza (olaparib; AstraZeneca Pharmaceuticals), Verzenio (Abemaciclib; Eli Lilly), Kisqali (Ribociclib; LEE011: Novartis Pharmaceuticals), Afinitor (Everolimus; Novartis), Faslodex (Fulvestrant Injection: AstraZeneca) and many more approved for the management of the HR-Positive/Her2negative breast cancer.
Ibrance is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. IBRANCE currently is approved in more than 90 countries.
It is used in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or fulvestrant in patients with disease progression following endocrine therapy for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
PIQRAY (BYL719; ALPESLIB) is an investigational, orally bioavailable, alpha-specific PI3K inhibitor developed by Novartis. In breast cancer cell lines harboring PIK3CA mutations, BYL719 has been shown to potentially inhibit the PI3K pathway and have antiproliferative effects. In addition, cancer cell lines with PIK3CA mutations were more sensitive to BYL719 than those without the mutation across a broad range of different cancers.
Verzenio (Abemaciclib) is indicated for the treatment of women with hormone receptor (HR)-positive in combination with fulvestrant. There are other kinase inhibitors recommended in combination to the conventional endocrine therapies. KISQALI is a kinase inhibitor used in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive breast cancer (BC). It is also used for human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.
There are other approved drugs in the market for the management of HR-positive/Her2-negative breast cancer.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Market Outlook
The HR-Positive/HER2-Negative Breast cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
As per the assessment by DelveInsight’s analysts, it has been observed that the market size of HR-positive/HER2-negative Breast in the 7MM countries was observed to be USD 5,237.2 million in 2017. Among the 7MM countries, the United States had the highest market size of HR-positive/HER2-negative breast cancer in 2017, of the total market. At present, the growth of market size for HR-positive/HER2-negative breast cancer is attributed to drugs that have been approved for HR-positive breast cancer by the US FDA.
As per the DelveInsight’s analyst, among the 7MM countries, Japan had the second highest market size of HR-positive/HER2-negative breast cancer in 2017. Among the EU-5 countries, Germany had the highest market size of HR-positive/HER2-negative breast cancer in 2017. At present, the growth of market size for HR-positive/HER2-negative breast cancer is attributed to drugs that have been approved for HR-positive breast cancer in EU-5 countries. The market size for HR-positive/HER2-negative breast cancer. At present, the growth of market size for HR-positive/HER2-negative breast cancer is attributed to drugs that have been approved for HR-positive breast cancer in EU-5 countries.
Advancement in development of novel drug candidate by various pharmaceutical companies the dynamics of HR-positive/HER2-Negative breast cancer market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019–2028. There are presently many drugs focused on the treatment of HR-positive/HER2-Negative breast cancer, which are expected to enter the market during the forecast period [2019–2028].
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer– Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of HR-positive/Her2-negative breast cancer market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and advancement in the research and development of emerging therapies during the forecast period of 2019-2028. Companies across the globe are thoroughly working toward the development of new treatment therapies for HR-positive/HER2-negative breast cancer.
More than a dozen companies have shifted their focus towards this therapeutic area. To name a few: Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche Group Syndax Pharmaceuticals, Merck Sharp & Dohme Corp, Eagle Pharmaceuticals and others.
Tesetaxel is an investigational agent developed by Odonate Therapeutics, belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. This is an orally administered chemotherapy. Odonate is hoping to qualify as a New Chemical Entity (NCE) if and when a New Drug Application (NDA) is submitted, retains the same taxane core as the approved taxanes, but includes the addition of two novels, nitrogen-containing functional group. This new formulation does not contain solubilizing agents contained in other taxane formulations which are known to cause hypersensitivity reactions. This is currently being accessed in phase III.
Sacituzumab govitecan (IMMU-132: Immunomedics) is an advanced product candidate, which is a novel, first-in-class antibody-drug conjugate (ADC). Sacituzumab govitecan is an ADC that contains SN-38, the active metabolite of irinotecan, approved by many Health Authorities, including the US Food and Drug Administration (FDA) as a chemotherapeutic for patients with cancer. SN-38 cannot be given directly to patients because of its toxicity and poor solubility.This novel drug is currently is in Phase III clinical developmental stage.
SHR6390 (Jiangsu HengRui Medicine) is Cyclin-dependent kinases 4 and 6 (CDK4/6) of cell cycle progression and are dysregulated in cancers. Inhibition of CDK4/6 induces G1 phase cell cycle arrest, therefore retards tumor growth. This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are up-regulated in many tumor cell types and play a key role in the regulation of cell cycle progression. SHR6390 has been recently accessed in phase II clinical trials.
Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Key Cross Competition
- Market Size by Therapies
- Drugs Uptake
- Pipeline Product Profiles
- Key Products and Key Players
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market
- Organize sales and marketing efforts by identifying the best opportunities for Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market
- To understand the future market competition in the Hormone Receptor (HR)-positive/Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market.
1. KEY INSIGHTS
2. HORMONE RECEPTOR (HR)-POSITIVE/ HUMAN EPIDERMAL RECEPTOR 2 (HER2)-NEGATIVE BREAST CANCER MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of HR-positive/HER2-negative in 2017
2.2. Total Market Share (%) Distribution of HR-positive/HER2-negative in 2028
3. DISEASE BACKGROUND AND OVERVIEW: HORMONE RECEPTOR (HR)-POSITIVE/ HUMAN EPIDERMAL RECEPTOR 2 (HER2)-NEGATIVE BREAST CANCER
3.1. Introduction
3.2. Types of Breast Cancer
3.2.1. Subtypes of Breast Cancer
3.2.2. Molecular Subtypes of Breast Cancer
3.3. Estrogen Receptor (ER)-Positive Breast Cancer
3.3.1. Estrogen Receptor
3.3.2. Estrogen Receptor 1 Mutations
3.4. Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer
3.4.1. Role of Estrogen Receptor Alpha (ER?) in Regulating Breast Cancer Metabolism
3.5. Symptoms of HR-Positive Breast Cancer
3.6. Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer
3.7. Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer
3.8. Diagnostic Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
3.8.1. American Society of Clinical Oncology (ASCO)
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Total Incidence of Breast Cancer in the 7MM
4.4. Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM
4.5. Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
4.6. Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
5. COUNTRY WISE-EPIDEMIOLOGY OF HORMONE RECEPTOR (HR) POSITIVE BREAST CANCER
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Incidence of Breast Cancer in the United States
5.1.3. Incidence of Breast Cancer Cases by Menopausal Status in the United States
5.1.4. Stage-Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States
5.1.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States
5.1.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States
5.1.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States
5.2. EU5 Countries
5.3. Germany
5.3.1. Assumptions and Rationale
5.3.2. Total Incidence of Breast Cancer in Germany
5.3.3. Incidence of Breast Cancer Cases by Menopausal Status in Germany
5.3.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany
5.3.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany
5.3.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Germany
5.3.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Germany
5.4. France
5.4.1. Assumptions and Rationale
5.4.2. Total Incidence of Breast Cancer in France
5.4.3. Incidence of Breast Cancer Cases by Menopausal Status in France
5.4.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France
5.4.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France
5.4.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France
5.4.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France
5.5. Italy
5.5.1. Assumptions and Rationale
5.5.2. Total Incidence of Breast Cancer in Italy
5.5.3. Incidence of Breast Cancer Cases by Menopausal Status in Italy
5.5.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy
5.5.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy
5.5.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy
5.5.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy
5.6. Spain
5.6.1. Assumptions and Rationale
5.6.2. Total Incidence of Breast Cancer in Spain
5.6.3. Incidence of Breast Cancer by Menopausal Status in Spain
5.6.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain
5.6.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain
5.6.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause Cases by Molecular Subtype in Spain
5.6.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause Cases by Molecular Subtype in Spain
5.7. The United Kingdom
5.7.1. Assumptions and Rationale
5.7.2. Total Incidence of Breast Cancer in the United Kingdom
5.7.3. Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom
5.7.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom (2017–2028)
5.7.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom
5.7.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom
5.7.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Total Incidence of Breast Cancer in Japan
5.8.3. Incidence of Breast Cancer Cases by Menopausal Status in Japan
5.8.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028)
5.8.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan
5.8.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Japan
5.8.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Japan
6. TREATMENT OF ESTROGEN-RECEPTOR (ER)-POSITIVE BREAST CANCER
6.1. Treatment Algorithm of Estrogen Receptor (ER)-Positive Breast Cancer
6.2. Treatment Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
6.2.1. American Society of Clinical Oncology (ASCO) Clinical Practice Guideline: Adjuvant Endocrine Therapy for Women with Hormone-receptor-positive Breast Cancer
6.2.2. Italian Association of Medical Oncology (AIOM): Adjuvant Endocrine Therapy in Premenopausal Patients with Hormone-receptor-positive Early Breast Cancer
6.2.3. The Japanese Breast Cancer Society: Clinical Practice Guideline for systemic treatment of breast cancer
7. MARKETED PRODUCTS
7.1. Ibrance (Palbociclib): Pfizer
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Clinical Development
7.1.4. Safety and efficacy
7.1.5. Product Profile
7.2. PIQRAY (Alpelisib; BYL719): Novartis
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Lynparza (olaparib): AstraZeneca Pharmaceuticals
7.3.1. Product Description
7.3.2. Regulatory Milestones
7.3.3. Clinical Development
7.3.4. Safety and efficacy
7.3.5. Product Profile
7.4. Verzenio (Abemaciclib): Eli Lilly
7.4.1. Product Description
7.4.2. Regulatory Milestones
7.4.3. Clinical Development
7.4.4. Safety and efficacy
7.4.5. Product Profile
7.5. Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals
7.5.1. Description
7.5.2. Regulatory Milestones
7.5.3. Clinical Development
7.5.4. Safety and efficacy
7.5.5. Product Profile
7.6. Afinitor (Everolimus): Novartis
7.6.1. Product Description
7.6.2. Regulatory Milestones
7.6.3. Clinical Development
7.6.4. Safety and efficacy
7.6.5. Product Profile
7.7. Faslodex (Fulvestrant) Injection: AstraZeneca
7.7.1. Description
7.7.2. Regulatory Milestones
7.7.3. Clinical Development
7.7.4. Safety and efficacy
7.7.5. Product Profile
7.8. Arimidex (Anastrozole): AstraZeneca
7.8.1. Description
7.8.2. Regulatory Milestones
7.8.3. Clinical Development
7.8.4. Safety and efficacy
7.8.5. Product Profile
7.9. Aromasin (Exemestane): Pharmacia and Upjohn Company
7.9.1. Product Description
7.9.2. Regulatory Milestones
7.9.3. Clinical Development
7.9.4. Safety and Efficacy
7.9.5. Product Profile
7.10. Femara (Letrozole): Novartis Pharmaceuticals
7.10.1. Product Description
7.10.2. Regulatory Milestones
7.10.3. Clinical Development
7.10.4. Safety and efficacy
7.10.5. Product Profile
8. UNMET NEEDS
9. EMERGING DRUGS
9.1. Key Cross Competition
9.2. SHR6390: Jiangsu HengRui Medicine Co.
9.2.1. Product Description
9.2.2. Clinical Development
9.2.3. Safety and Efficacy
9.2.4. Product Profile
9.3. TESETAXEL: Odonate Therapeutics
9.3.1. Product Description
9.3.2. Other Development Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. RAD1901: Radius Pharmaceuticals
9.4.1. Product Description
9.4.2. Other Development Activities
9.4.3. Clinical Development
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. IMMU-132 (Sacituzumab Govitecan): Immunomedics
9.5.1. Product Description
9.5.2. Other Development Activities
9.5.3. Clinical Development
9.5.4. Product Profile
9.6. Ipatasertib (RG7440): Roche Group
9.6.1. Product Description
9.6.2. Other Development Activities
9.6.3. Clinical Development
9.6.4. Product Profile
9.7. Venclexta: Roche Group
9.7.1. Product Description
9.7.2. Other Development Activities
9.7.3. Clinical Development
9.7.4. Safety and Efficacy
9.7.5. Product Profile
9.8. Entinostat: Syndax Pharmaceuticals
9.8.1. Product Description
9.8.2. Other Developmental Activities
9.8.3. Clinical Development
9.8.4. Safety and Efficacy
9.8.5. Product Profile
9.9. Pembrolizumab (MK-3475): Merck Sharp and Dohme
9.9.1. Product Description
9.9.2. Other development Activities
9.9.3. Clinical Development
9.9.4. Product Profile
9.10. Eribulin Mesylate: Merck Sharp & Dohme Corp.
9.10.1. Product Description
9.10.2. Other development Activities
9.10.3. Clinical Development
9.10.4. Safety and Efficacy
9.10.5. Product Profile
9.11. MM-121: Merrimack Pharmaceuticals
9.11.1. Product Description
9.11.2. Other Development Activities
9.11.3. Clinical Development
9.11.4. Safety and Efficacy
9.11.5. Product Profile
9.12. GSK525762 (Molibresib): GlaxoSmithKline
9.12.1. Product Description
9.12.2. Other Development Activities
9.12.3. Clinical Development
9.12.4. Safety and Efficacy
9.12.5. Product Profile
9.13. SAPANISERTIB (TAK-228): Millennium Pharmaceuticals
9.13.1. Product Description
9.13.2. Other Development Activities
9.13.3. Clinical Development
9.13.4. Safety and Efficacy
9.13.5. Product Profile
9.14. Radium-223 dichloride: Bayer
9.14.1. Product Description
9.14.2. Other Development Activities
9.14.3. Clinical Development
9.14.4. Safety and Efficacy
9.14.5. Product Profile
9.15. EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals
9.15.1. Product Description
9.15.2. Other Development Activities
9.15.3. Clinical Development
9.15.4. Product Profile
10. HR+/HER2- POST MENOPAUSE BREAST CANCER: THE 7 MAJOR MARKET ANALYSIS
10.1. Key Findings
10.2. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM
10.3. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM
10.4. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM
10.5. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM
10.6. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM
11. THE UNITED STATES MARKET ANALYSIS
11.1. The United States Market Outlook
11.2. United States Market Size
11.2.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States
11.2.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United States
11.2.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United States
11.2.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States
11.2.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States
12. EU-5 MARKET ANALYSIS
12.1. EU-5 Market Outlook
12.2. Germany Market Size
12.2.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany
12.2.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Germany
12.2.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Germany
12.2.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany
12.2.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany
12.3. France Market Size
12.3.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France
12.3.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in France
12.3.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in France
12.3.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France
12.3.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France
12.4. Italy Market Size
12.4.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy
12.4.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Italy
12.4.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Italy
12.4.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy
12.4.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy
12.5. Spain Market Size
12.5.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain
12.5.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Spain
12.5.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Spain
12.5.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain
12.5.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain
12.6. The United Kingdom Market Size
12.6.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom
12.6.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom
12.6.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom
12.6.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom
12.6.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom
13. JAPAN MARKET OUTLOOK
13.1. Japan Market Size
13.1.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan
13.1.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Japan
13.1.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Japan
13.1.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan
13.1.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
16.1. Report Methodology
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
2. HORMONE RECEPTOR (HR)-POSITIVE/ HUMAN EPIDERMAL RECEPTOR 2 (HER2)-NEGATIVE BREAST CANCER MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share (%) Distribution of HR-positive/HER2-negative in 2017
2.2. Total Market Share (%) Distribution of HR-positive/HER2-negative in 2028
3. DISEASE BACKGROUND AND OVERVIEW: HORMONE RECEPTOR (HR)-POSITIVE/ HUMAN EPIDERMAL RECEPTOR 2 (HER2)-NEGATIVE BREAST CANCER
3.1. Introduction
3.2. Types of Breast Cancer
3.2.1. Subtypes of Breast Cancer
3.2.2. Molecular Subtypes of Breast Cancer
3.3. Estrogen Receptor (ER)-Positive Breast Cancer
3.3.1. Estrogen Receptor
3.3.2. Estrogen Receptor 1 Mutations
3.4. Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer
3.4.1. Role of Estrogen Receptor Alpha (ER?) in Regulating Breast Cancer Metabolism
3.5. Symptoms of HR-Positive Breast Cancer
3.6. Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer
3.7. Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer
3.8. Diagnostic Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
3.8.1. American Society of Clinical Oncology (ASCO)
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Total Incidence of Breast Cancer in the 7MM
4.4. Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM
4.5. Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
4.6. Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
5. COUNTRY WISE-EPIDEMIOLOGY OF HORMONE RECEPTOR (HR) POSITIVE BREAST CANCER
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Incidence of Breast Cancer in the United States
5.1.3. Incidence of Breast Cancer Cases by Menopausal Status in the United States
5.1.4. Stage-Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States
5.1.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States
5.1.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States
5.1.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States
5.2. EU5 Countries
5.3. Germany
5.3.1. Assumptions and Rationale
5.3.2. Total Incidence of Breast Cancer in Germany
5.3.3. Incidence of Breast Cancer Cases by Menopausal Status in Germany
5.3.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany
5.3.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany
5.3.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Germany
5.3.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Germany
5.4. France
5.4.1. Assumptions and Rationale
5.4.2. Total Incidence of Breast Cancer in France
5.4.3. Incidence of Breast Cancer Cases by Menopausal Status in France
5.4.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France
5.4.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France
5.4.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France
5.4.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France
5.5. Italy
5.5.1. Assumptions and Rationale
5.5.2. Total Incidence of Breast Cancer in Italy
5.5.3. Incidence of Breast Cancer Cases by Menopausal Status in Italy
5.5.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy
5.5.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy
5.5.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy
5.5.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy
5.6. Spain
5.6.1. Assumptions and Rationale
5.6.2. Total Incidence of Breast Cancer in Spain
5.6.3. Incidence of Breast Cancer by Menopausal Status in Spain
5.6.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain
5.6.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain
5.6.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause Cases by Molecular Subtype in Spain
5.6.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause Cases by Molecular Subtype in Spain
5.7. The United Kingdom
5.7.1. Assumptions and Rationale
5.7.2. Total Incidence of Breast Cancer in the United Kingdom
5.7.3. Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom
5.7.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom (2017–2028)
5.7.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United Kingdom
5.7.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom
5.7.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Total Incidence of Breast Cancer in Japan
5.8.3. Incidence of Breast Cancer Cases by Menopausal Status in Japan
5.8.4. Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028)
5.8.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan
5.8.6. Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Japan
5.8.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Japan
6. TREATMENT OF ESTROGEN-RECEPTOR (ER)-POSITIVE BREAST CANCER
6.1. Treatment Algorithm of Estrogen Receptor (ER)-Positive Breast Cancer
6.2. Treatment Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer
6.2.1. American Society of Clinical Oncology (ASCO) Clinical Practice Guideline: Adjuvant Endocrine Therapy for Women with Hormone-receptor-positive Breast Cancer
6.2.2. Italian Association of Medical Oncology (AIOM): Adjuvant Endocrine Therapy in Premenopausal Patients with Hormone-receptor-positive Early Breast Cancer
6.2.3. The Japanese Breast Cancer Society: Clinical Practice Guideline for systemic treatment of breast cancer
7. MARKETED PRODUCTS
7.1. Ibrance (Palbociclib): Pfizer
7.1.1. Product Description
7.1.2. Regulatory Milestones
7.1.3. Clinical Development
7.1.4. Safety and efficacy
7.1.5. Product Profile
7.2. PIQRAY (Alpelisib; BYL719): Novartis
7.2.1. Product Description
7.2.2. Regulatory Milestones
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. Lynparza (olaparib): AstraZeneca Pharmaceuticals
7.3.1. Product Description
7.3.2. Regulatory Milestones
7.3.3. Clinical Development
7.3.4. Safety and efficacy
7.3.5. Product Profile
7.4. Verzenio (Abemaciclib): Eli Lilly
7.4.1. Product Description
7.4.2. Regulatory Milestones
7.4.3. Clinical Development
7.4.4. Safety and efficacy
7.4.5. Product Profile
7.5. Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals
7.5.1. Description
7.5.2. Regulatory Milestones
7.5.3. Clinical Development
7.5.4. Safety and efficacy
7.5.5. Product Profile
7.6. Afinitor (Everolimus): Novartis
7.6.1. Product Description
7.6.2. Regulatory Milestones
7.6.3. Clinical Development
7.6.4. Safety and efficacy
7.6.5. Product Profile
7.7. Faslodex (Fulvestrant) Injection: AstraZeneca
7.7.1. Description
7.7.2. Regulatory Milestones
7.7.3. Clinical Development
7.7.4. Safety and efficacy
7.7.5. Product Profile
7.8. Arimidex (Anastrozole): AstraZeneca
7.8.1. Description
7.8.2. Regulatory Milestones
7.8.3. Clinical Development
7.8.4. Safety and efficacy
7.8.5. Product Profile
7.9. Aromasin (Exemestane): Pharmacia and Upjohn Company
7.9.1. Product Description
7.9.2. Regulatory Milestones
7.9.3. Clinical Development
7.9.4. Safety and Efficacy
7.9.5. Product Profile
7.10. Femara (Letrozole): Novartis Pharmaceuticals
7.10.1. Product Description
7.10.2. Regulatory Milestones
7.10.3. Clinical Development
7.10.4. Safety and efficacy
7.10.5. Product Profile
8. UNMET NEEDS
9. EMERGING DRUGS
9.1. Key Cross Competition
9.2. SHR6390: Jiangsu HengRui Medicine Co.
9.2.1. Product Description
9.2.2. Clinical Development
9.2.3. Safety and Efficacy
9.2.4. Product Profile
9.3. TESETAXEL: Odonate Therapeutics
9.3.1. Product Description
9.3.2. Other Development Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. RAD1901: Radius Pharmaceuticals
9.4.1. Product Description
9.4.2. Other Development Activities
9.4.3. Clinical Development
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. IMMU-132 (Sacituzumab Govitecan): Immunomedics
9.5.1. Product Description
9.5.2. Other Development Activities
9.5.3. Clinical Development
9.5.4. Product Profile
9.6. Ipatasertib (RG7440): Roche Group
9.6.1. Product Description
9.6.2. Other Development Activities
9.6.3. Clinical Development
9.6.4. Product Profile
9.7. Venclexta: Roche Group
9.7.1. Product Description
9.7.2. Other Development Activities
9.7.3. Clinical Development
9.7.4. Safety and Efficacy
9.7.5. Product Profile
9.8. Entinostat: Syndax Pharmaceuticals
9.8.1. Product Description
9.8.2. Other Developmental Activities
9.8.3. Clinical Development
9.8.4. Safety and Efficacy
9.8.5. Product Profile
9.9. Pembrolizumab (MK-3475): Merck Sharp and Dohme
9.9.1. Product Description
9.9.2. Other development Activities
9.9.3. Clinical Development
9.9.4. Product Profile
9.10. Eribulin Mesylate: Merck Sharp & Dohme Corp.
9.10.1. Product Description
9.10.2. Other development Activities
9.10.3. Clinical Development
9.10.4. Safety and Efficacy
9.10.5. Product Profile
9.11. MM-121: Merrimack Pharmaceuticals
9.11.1. Product Description
9.11.2. Other Development Activities
9.11.3. Clinical Development
9.11.4. Safety and Efficacy
9.11.5. Product Profile
9.12. GSK525762 (Molibresib): GlaxoSmithKline
9.12.1. Product Description
9.12.2. Other Development Activities
9.12.3. Clinical Development
9.12.4. Safety and Efficacy
9.12.5. Product Profile
9.13. SAPANISERTIB (TAK-228): Millennium Pharmaceuticals
9.13.1. Product Description
9.13.2. Other Development Activities
9.13.3. Clinical Development
9.13.4. Safety and Efficacy
9.13.5. Product Profile
9.14. Radium-223 dichloride: Bayer
9.14.1. Product Description
9.14.2. Other Development Activities
9.14.3. Clinical Development
9.14.4. Safety and Efficacy
9.14.5. Product Profile
9.15. EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals
9.15.1. Product Description
9.15.2. Other Development Activities
9.15.3. Clinical Development
9.15.4. Product Profile
10. HR+/HER2- POST MENOPAUSE BREAST CANCER: THE 7 MAJOR MARKET ANALYSIS
10.1. Key Findings
10.2. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM
10.3. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM
10.4. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM
10.5. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM
10.6. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM
11. THE UNITED STATES MARKET ANALYSIS
11.1. The United States Market Outlook
11.2. United States Market Size
11.2.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States
11.2.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United States
11.2.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United States
11.2.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States
11.2.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States
12. EU-5 MARKET ANALYSIS
12.1. EU-5 Market Outlook
12.2. Germany Market Size
12.2.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany
12.2.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Germany
12.2.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Germany
12.2.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany
12.2.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany
12.3. France Market Size
12.3.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France
12.3.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in France
12.3.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in France
12.3.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France
12.3.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France
12.4. Italy Market Size
12.4.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy
12.4.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Italy
12.4.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Italy
12.4.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy
12.4.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy
12.5. Spain Market Size
12.5.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain
12.5.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Spain
12.5.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Spain
12.5.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain
12.5.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain
12.6. The United Kingdom Market Size
12.6.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom
12.6.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom
12.6.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom
12.6.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom
12.6.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom
13. JAPAN MARKET OUTLOOK
13.1. Japan Market Size
13.1.1. Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan
13.1.2. Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Japan
13.1.3. Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Japan
13.1.4. First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan
13.1.5. Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
16.1. Report Methodology
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Total Incidence of Breast Cancer in the 7MM (2017–2028)
Table 2: Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028)
Table 3: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Table 4: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Table 5: Total Incidence of Breast Cancer in the United States (2017–2028)
Table 6: Incidence of Breast Cancer by Menopausal Status in the United States (2017–2028)
Table 7: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Table 8: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Table 9: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028)
Table 10: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028)
Table 11: Incidence of Breast Cancer in Germany (2017–2028)
Table 12: Incidence of Breast Cancer by Menopausal Status in Germany (2017–2028)
Table 13: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Table 14: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Table 15: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028)
Table 16: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028)
Table 17: Total Incidence of Breast Cancer in France (2017–2028)
Table 18: Incidence of Breast Cancer by Menopausal Status in France (2017–2028)
Table 19: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Table 20: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Table 21: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028)
Table 22: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028)
Table 23: Total Incidence of Breast Cancer in Italy (2017–2028)
Table 24: Incidence of Breast Cancer by Menopausal Status in Italy (2017–2028)
Table 25: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Table 26: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Table 27: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028)
Table 28: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028)
Table 29: Total Incidence of Breast Cancer in Spain (2017–2028)
Table 30: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2028)
Table 31: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Table 32: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Table 33: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028)
Table 34: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028)
Table 35: Total Incidence of Breast Cancer in the United Kingdom (2017–2028)
Table 36: Incidence of Breast Cancer by Menopausal Status in the United Kingdom (2017–2028)
Table 37: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Table 38: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Table 39: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Table 40: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Table 41: Total Incidence of Breast Cancer in Japan (2017–2028)
Table 42: Incidence of Breast Cancer by Menopausal Status in Japan (2017–2028)
Table 43: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028)
Table 44: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan (2017–2028)
Table 45: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)
Table 46: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)
Table 47: Classification of Aromatase Inhibitors
Table 48: Summary of All Recommendations (Original Recommendations and Focused Update Recommendations)
Table 49: Ibrance, Clinical Trial Description, 2019
Table 50: PIQRAY, Clinical Trial Description, 2019
Table 51: Olaparib, Clinical Trial Description, 2019
Table 52: Verzenio, Clinical Trial Description, 2019
Table 53: KISQALI, Clinical Trial Description, 2019
Table 54: Faslodex, Clinical Trial Description, 2019
Table 55: Arimidex, Clinical Trial Description, 2019
Table 56: SHR6390, Clinical Trial Description, 2019
Table 57:, Tesetaxel, Clinical Trial Description, 2019
Table 58: Elacestrant (RAD1901), Clinical Trial Description, 2019
Table 59: IMMU-132, Clinical Trial Description, 2019
Table 60: Ipatasertib, Clinical Trial Description, 2019
Table 61: Venetoclax, Clinical Trial Description, 2019
Table 62: Entinostat, Clinical Trial Description, 2019
Table 63: Pembrolizumab, Clinical Trial Description, 2019
Table 64: Eribulin Mesylate, Clinical Trial Description, 2019
Table 65: Seribantumab, Clinical Trial Description, 2019
Table 66: GSK525762 (Molibresib), Clinical Trial Description, 2019
Table 67: TAK-228 (INK128, MLN0128), Clinical Trial Description, 2019
Table 68: Radium 223 dichloride (BAY88-8223), Clinical Trial Description, 2019
Table 69: EGL-5385-C-1701(fulvestrant): Clinical Trial Description, 2019
Table 70: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM, USD Millions (2017–2028)
Table 71: 7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 72:7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 73: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2028)
Table 74: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2028)
Table 75: Novel drugs recently approved for treating HR-positive/ HER2-negative Breast Cancer
Table 76: Expected Launch Date of Emerging Drugs in the United States
Table 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2028)
Table 78: United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 79:United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2028)
Table 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2028)
Table 82: Expected Launch Date of Emerging Drugs in EU-5 Countries
Table 83: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2028)
Table 84: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 85:Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 86: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2028)
Table 87: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2028)
Table 88: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France, USD Millions (2017–2028)
Table 89: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 90: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2028)
Table 91: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2028)
Table 92: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy, USD Millions (2017–2028)
Table 93: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 94:Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 95: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2028)
Table 96: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2028)
Table 97: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain, USD Millions (2017–2028)
Table 98: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 99:Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 100: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2028)
Table 101: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2028)
Table 102: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom, USD Millions (2017–2028)
Table 103: The United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 104:The United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 105: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom, in USD Million (2017–2028)
Table 106: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom, in USD Million (2017–2028)
Table 107: Expected Launch Date of Emerging Drugs in Japan
Table 108: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan, USD Millions (2017–2028)
Table 109: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 110:Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 111: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2028)
Table 112: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2028)
Table 1: Total Incidence of Breast Cancer in the 7MM (2017–2028)
Table 2: Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028)
Table 3: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Table 4: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Table 5: Total Incidence of Breast Cancer in the United States (2017–2028)
Table 6: Incidence of Breast Cancer by Menopausal Status in the United States (2017–2028)
Table 7: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Table 8: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Table 9: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028)
Table 10: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in the United States (2017–2028)
Table 11: Incidence of Breast Cancer in Germany (2017–2028)
Table 12: Incidence of Breast Cancer by Menopausal Status in Germany (2017–2028)
Table 13: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Table 14: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Table 15: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028)
Table 16: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype Cases in Germany (2017–2028)
Table 17: Total Incidence of Breast Cancer in France (2017–2028)
Table 18: Incidence of Breast Cancer by Menopausal Status in France (2017–2028)
Table 19: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Table 20: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in France (2017–2028)
Table 21: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028)
Table 22: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in France (2017–2028)
Table 23: Total Incidence of Breast Cancer in Italy (2017–2028)
Table 24: Incidence of Breast Cancer by Menopausal Status in Italy (2017–2028)
Table 25: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Table 26: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Italy (2017–2028)
Table 27: Diagnosed Incidence of Early Stage Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028)
Table 28: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post menopause by Molecular Subtype in Italy (2017–2028)
Table 29: Total Incidence of Breast Cancer in Spain (2017–2028)
Table 30: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2028)
Table 31: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Table 32: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Spain (2017–2028)
Table 33: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028)
Table 34: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Spain (2017–2028)
Table 35: Total Incidence of Breast Cancer in the United Kingdom (2017–2028)
Table 36: Incidence of Breast Cancer by Menopausal Status in the United Kingdom (2017–2028)
Table 37: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Table 38: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the UK (2017–2028)
Table 39: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Table 40: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United Kingdom (2017–2028)
Table 41: Total Incidence of Breast Cancer in Japan (2017–2028)
Table 42: Incidence of Breast Cancer by Menopausal Status in Japan (2017–2028)
Table 43: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Japan (2017–2028)
Table 44: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the Japan (2017–2028)
Table 45: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)
Table 46: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in Japan (2017–2028)
Table 47: Classification of Aromatase Inhibitors
Table 48: Summary of All Recommendations (Original Recommendations and Focused Update Recommendations)
Table 49: Ibrance, Clinical Trial Description, 2019
Table 50: PIQRAY, Clinical Trial Description, 2019
Table 51: Olaparib, Clinical Trial Description, 2019
Table 52: Verzenio, Clinical Trial Description, 2019
Table 53: KISQALI, Clinical Trial Description, 2019
Table 54: Faslodex, Clinical Trial Description, 2019
Table 55: Arimidex, Clinical Trial Description, 2019
Table 56: SHR6390, Clinical Trial Description, 2019
Table 57:, Tesetaxel, Clinical Trial Description, 2019
Table 58: Elacestrant (RAD1901), Clinical Trial Description, 2019
Table 59: IMMU-132, Clinical Trial Description, 2019
Table 60: Ipatasertib, Clinical Trial Description, 2019
Table 61: Venetoclax, Clinical Trial Description, 2019
Table 62: Entinostat, Clinical Trial Description, 2019
Table 63: Pembrolizumab, Clinical Trial Description, 2019
Table 64: Eribulin Mesylate, Clinical Trial Description, 2019
Table 65: Seribantumab, Clinical Trial Description, 2019
Table 66: GSK525762 (Molibresib), Clinical Trial Description, 2019
Table 67: TAK-228 (INK128, MLN0128), Clinical Trial Description, 2019
Table 68: Radium 223 dichloride (BAY88-8223), Clinical Trial Description, 2019
Table 69: EGL-5385-C-1701(fulvestrant): Clinical Trial Description, 2019
Table 70: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM, USD Millions (2017–2028)
Table 71: 7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 72:7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 73: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2028)
Table 74: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2028)
Table 75: Novel drugs recently approved for treating HR-positive/ HER2-negative Breast Cancer
Table 76: Expected Launch Date of Emerging Drugs in the United States
Table 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2028)
Table 78: United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 79:United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2028)
Table 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2028)
Table 82: Expected Launch Date of Emerging Drugs in EU-5 Countries
Table 83: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2028)
Table 84: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 85:Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 86: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2028)
Table 87: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2028)
Table 88: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France, USD Millions (2017–2028)
Table 89: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 90: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2028)
Table 91: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2028)
Table 92: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy, USD Millions (2017–2028)
Table 93: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 94:Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 95: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2028)
Table 96: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2028)
Table 97: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain, USD Millions (2017–2028)
Table 98: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 99:Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 100: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2028)
Table 101: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2028)
Table 102: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom, USD Millions (2017–2028)
Table 103: The United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 104:The United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 105: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom, in USD Million (2017–2028)
Table 106: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom, in USD Million (2017–2028)
Table 107: Expected Launch Date of Emerging Drugs in Japan
Table 108: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan, USD Millions (2017–2028)
Table 109: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2028)
Table 110:Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2028)
Table 111: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2028)
Table 112: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2028)
LIST OF FIGURES
Figure 1: Molecular Subtypes of Breast Cancer
Figure 2: Working of Estrogen Receptor
Figure 3: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains.
Figure 4: ER pathway and mechanisms of resistance. Estrogen-bound estrogen receptor (ER), in association with a variety of coactivators and co-repressors, exerts its classical genomic action as a transcription factor through the estrogen response element (ERE) of target genes.
Figure 5: Metabolism of Estrogen Receptor-Positive Breast Cancer
Figure 6: Lifestyle-related Breast Cancer Risk Factors
Figure 7: Diagnosis of ER-Positive Breast Cancer
Figure 8: Assays for Measuring Estrogen and Progesterone Receptor
Figure 9: Essential Elements Required for Accurate Testing of ERa And PGr Status In Breast Cancer by Immunohistochemistry.
Figure 10: Total Incidence of Breast Cancer in the 7MM (2017–2028)
Figure 11:Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028)
Figure 12: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Figure 13: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Figure 14: Total Incidence of Breast Cancer in the United States (2017–2028)
Figure 15: Incidence of Breast Cancer Cases by Menopausal Status in the United States (2017–2028)
Figure 16: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Figure 17: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Figure 18: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028)
Figure 19: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028)
Figure 20: Total Incidence of Breast Cancer in Germany (2017–2028)
Figure 21: Incidence of Breast Cancer Cases by Menopausal Status in Germany (2017–2028)
Figure 22: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Figure 23: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Figure 24: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028)
Figure 25: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028)
Figure 26: Total Incidence of Breast Cancer in France (2017–2028)
Figure 27: Incidence of Breast Cancer Cases by Menopausal Status in France (2017–2028)
Figure 28: Stage Specif
Figure 1: Molecular Subtypes of Breast Cancer
Figure 2: Working of Estrogen Receptor
Figure 3: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains.
Figure 4: ER pathway and mechanisms of resistance. Estrogen-bound estrogen receptor (ER), in association with a variety of coactivators and co-repressors, exerts its classical genomic action as a transcription factor through the estrogen response element (ERE) of target genes.
Figure 5: Metabolism of Estrogen Receptor-Positive Breast Cancer
Figure 6: Lifestyle-related Breast Cancer Risk Factors
Figure 7: Diagnosis of ER-Positive Breast Cancer
Figure 8: Assays for Measuring Estrogen and Progesterone Receptor
Figure 9: Essential Elements Required for Accurate Testing of ERa And PGr Status In Breast Cancer by Immunohistochemistry.
Figure 10: Total Incidence of Breast Cancer in the 7MM (2017–2028)
Figure 11:Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2028)
Figure 12: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM
Figure 13: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM
Figure 14: Total Incidence of Breast Cancer in the United States (2017–2028)
Figure 15: Incidence of Breast Cancer Cases by Menopausal Status in the United States (2017–2028)
Figure 16: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Figure 17: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in the United States (2017–2028)
Figure 18: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028)
Figure 19: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype in the United States (2017–2028)
Figure 20: Total Incidence of Breast Cancer in Germany (2017–2028)
Figure 21: Incidence of Breast Cancer Cases by Menopausal Status in Germany (2017–2028)
Figure 22: Stage Specific Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Figure 23: Stage Specific Diagnosed Incidence of Breast Cancer in Post-Menopausal Women in Germany (2017–2028)
Figure 24: Diagnosed Incidence of Early Stage Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028)
Figure 25: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-Menopausal by Molecular Subtype Cases in Germany (2017–2028)
Figure 26: Total Incidence of Breast Cancer in France (2017–2028)
Figure 27: Incidence of Breast Cancer Cases by Menopausal Status in France (2017–2028)
Figure 28: Stage Specif
